Discover how BioCryst achieved record Q2 2025 results with ORLADEYO's 45% revenue growth, strategic moves, and confident leadership transition.

More Americans Are Rethinking Collagen, Glucosamine, and Pills in 2025 as Public Curiosity Shifts Toward Ingredient-First ...

ZUG, Switzerland and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Cash runway extended into the second half of 2026 •     Average sales price per share was over 10% higher than the June 2025 public offering price ...

Pancreatitis, vision loss ... the risks of drugs such as Ozempic can sound scary. But what does the evidence show?

Alaska Gov. Mike Dunleavy, who has spent much of his career in education, chose not to sign or veto the state’s new CPA ...

WinRevair’s Phase 3 HYPERION trial was stopped early for efficacy, with positive top-line results announced in the month ...

A quick look at the Fraud and ID Theft Maps of the Federal Trade Commission (FTC) shows 841,810 reports of ID theft by the ...